Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disulfiram and Cisplatin in Refractory Germ Cell Tumors
NCT03950830Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of disulfiram in germ cell tumor (GCT), sponsored by National Cancer Institute. Started May 2019; status: completed.
02
Drugs
disulfiram
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT03950830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950830.